1. Long‐term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. Issue 3 (March 2014) Authors: Ghobrial, Irene M.; Witzig, Thomas E.; Gertz, Morie; LaPlant, Betsy; Hayman, Suzanne; Camoriano, John; Lacy, Martha; Bergsagel, P. Leif; Chuma, Stacey; DeAngelo, Daniel; Treon, Steven P. Journal: American journal of hematology Issue: Volume 89:Issue 3(2014:Mar.) Page Start: 237 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Patient‐Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. (23rd August 2018) Authors: El‐Jawahri, Areej; Nelson‐Lowe, Margaret; VanDusen, Harry; Traeger, Lara; Abel, Gregory A.; Greer, Joseph A.; Fathi, Amir; Steensma, David P.; LeBlanc, Thomas W.; Li, Zhigang; DeAngelo, Daniel; Wadleigh, Martha; Hobbs, Gabriela; Foster, Julia; Brunner, Andrew; Amrein, Philip; Stone, Richard M.; T... Journal: Oncologist Issue: Volume 24:Number 2(2019) Page Start: 247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗